Trials / Recruiting
RecruitingNCT06989359
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- ADARx Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ADX-038 Dose Level 2 | siRNA duplex oligonucleotide |
| DRUG | ADX-038 Dose Level 1 | siRNA duplex oligonucleotide |
Timeline
- Start date
- 2025-08-28
- Primary completion
- 2027-07-01
- Completion
- 2028-07-01
- First posted
- 2025-05-25
- Last updated
- 2026-03-02
Locations
12 sites across 4 countries: United States, Australia, Hong Kong, South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06989359. Inclusion in this directory is not an endorsement.